| Patent Number |
Title Of Patent |
Date Issued |
| 7345033 |
Carbamoyl-and thiocarbamoyl-phosphonates and pharmaceutical compositions comprising them |
March 18, 2008 |
| The present invention provides a compound of the following formula I: R.sup.3--NH--C(.dbd.X)--P(.dbd.O)OR.sup.1OR.sup.2 including pharmaceutically acceptable salts, solvates, hydrates and polymorphs of the compounds of formula I, as well as geometrical isomers and optically active f |
| 7034006 |
Use of lipid conjugates in the treatment of disease |
April 25, 2006 |
| The invention provides novel methods for treating disease based upon the medicinal use of lipids and phospholipids covalently bound to physiologically acceptable monomers or polymers. Phosphatidylethanolamine moieties conjugated to physiologically acceptable monomers and polymers (PE |
| 7008645 |
Method of inhibiting restenosis using bisphosphonates |
March 7, 2006 |
| A method of inhibiting the activity or production of cytokines or growth factors associated with vascular restenosis, by administering to an individual an effective amount of an active ingredient comprising a bisphosphonate particle or a bisphosphonate particulate. The bisphosphonate |
| 6984400 |
Method of treating restenosis using bisphosphonate nanoparticles |
January 10, 2006 |
| A method of treating or preventing restenosis by administering to an individual an effective amount of an active ingredient comprising a bisphosphonate particle or a bisphosphonate particulate. The bisphosphonate may be encapsulated, embedded or adsorbed within the particle, disperse |
| 6673798 |
PDGF receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical co |
January 6, 2004 |
| A purified tyrphostin of a general formula: ##STR1##wherein, for Compound I, R.sub.6 is either at position 6 or at position 7, or, for Compound II, R.sub.6 is either at position 6 or at position 8. |
| 6541454 |
Phosphonates, biphosphonates and pharmaceutical compositions containing them |
April 1, 2003 |
| A method for treating patients having calcium related disorders includes using di- or tripeptide derivatives of bisphosphonates to enhance oral bioavailability of such compounds. |
| 6358954 |
PDGF receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical co |
March 19, 2002 |
| An isometric enriched tyrphostin of a general formula: ##STR1##wherein, for Compound I, the tyrphostin is enriched either for R.sub.6 at position 6 or for R.sub.6 at position 7, or, for Compound II, the tyrphostin is enriched either for R.sub.6 at position 6 or for R.sub.6 at positio |
| 5932580 |
PDGF receptor kinase inhibitory compounds their preparation and compositions |
August 3, 1999 |
| PDGF receptor kinase inhibitory compounds of the quinoxaline family, methods for their synthesis and containment is slow release pharmaceutical preparations, and their use for treatment of proliferative malignant and non-malignant diseases or disorders by local or systemic application. A |
| 5338731 |
Bisphosphonates, processes for preparation and pharmaceutical compositions containing the same |
August 16, 1994 |
| Bisphosphonate compounds are of the Formula (I): ##STR1## wherein Y is .dbd.O or .dbd.N--OH and n is from 3 to 24, and further wherein when Y is .dbd.O, (i) R.sub.1 is hydrogen and R.sub.2 is sodium, or (ii) R.sub.1 is sodium and R.sub.2 is methyl, and when Y is .dbd.N--OH, R.sub |
| 5312954 |
Bis- and tetrakis-phosphonates useful for treating calcium related disorders |
May 17, 1994 |
| Novel bisphosphonates comprise compounds of the formula (I) ##STR1## wherein m and l are independently 1 or 2; R.sub.1 represents hydrogen, a lower alkyl group, or an alkali metal cation; R.sub.2 represents hydrogen, a lower alkyl group or an alkali metal cation; Y represents .dbd.0 |
| 5196409 |
Bisphosphonates, pharmaceutical compositions, and process for the treatment of irregularities in |
March 23, 1993 |
| Novel bisphosphonates comprise compounds of the formula (I) ##STR1## wherein m and l are independently 1 or 2; R.sub.1 represents hydrogen, a lower alkyl group, or an alkali metal cation; R.sub.2 represents hydrogen, a lower alkyl group or an alkali metal cation; Y represents .dbd.0 |
